Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2025 07:00 ET | Source: Cullgen Inc.

Cullgen Completes Enrollment in Phase 1 Trial of its Novel Non-Opioid Pain Product Candidate CG001419

SAN DIEGO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein...
September 17, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic...
September 17, 2025 01:00 ET | Source: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended...
September 17, 2025 01:00 ET | Source: Navigator Medicines INC

Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases

Positive safety and tolerability profile of NAV-240 in Phase 1a study support further developmentPhase 1b study fully enrolled and data expected in early 2026Further clinical development of NAV-240 to...
September 10, 2025 06:29 ET | Source: Research and Markets

Europe Commercial Greenhouse Forecast and Company Analysis Report 2025-2033 Featuring Berry, RICHEL, Certhon Build, Argus, LOGIQS, LumiGrow, Keder Greenhouse ,Agra Tech, Hort, American Wire

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Europe Commercial Greenhouse Market Size and Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.The Europe Commercial...
September 10, 2025 01:21 ET | Source: ZenaTech Inc.

ZenaTech firma oferta para adquirir una empresa de gestión de almacenes e inventarios con contratos establecidos a largo plazo con el Departamento de Defensa de EE. UU., acelerando la expansión de DaaS en la costa este

VANCOUVER, Columbia Británica, Sept. 09, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), un proveedor de soluciones de tecnología empresarial,...
September 09, 2025 15:20 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding...
August 21, 2025 10:17 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The...
August 14, 2025 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE...
August 14, 2025 06:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in...